ClinicalTrials.gg
RecruitingNCT05492123Updated Jan 5, 2024

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

A Phase 2 interventional study of Nivolumab 40 mg in 4 ml Injection and Ipilimumab 200 MG in 40 ML Injection in Uterine Cervical Neoplasms, sponsored by Hospital Israelita Albert Einstein. Recruiting at 14 sites in Brazil. Open to female participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Hospital Israelita Albert Einstein · Phase 2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing nivolumab in Uterine Cervical Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. Nivolumab · Uterine Cervical Neoplasms.

Planned enrollment
4th of 14
112 · median 33
Started
2022
the only one that year
Phase 2
9 of 14
3 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Hospital Israelita Albert Einstein

Among the 14 studies testing nivolumab in Uterine Cervical Neoplasms, this one is the 4th largest by planned enrollment, is the only one that started in 2022, is one of 9 in phase 2, and was the 10th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

4 of the 14 studies testing nivolumab in Uterine Cervical Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 95 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nivolumab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.

Read the detailed description

Patients with adenocarcinoma or squamous cell carcinoma of the cervix, FIGO Stage IB2-IB3 node positive or Stage IIB-IVA will be randomized to conventional cisplatin-based chemo-radiation or to 4 cycles of induction immunotherapy with nivolumab 1mg/kg and ipilimumab 3mg/kg every 3 weeks, followed by cisplatin chemo-radiation with concurrent nivolumab 240mg every 2 weeks. Primary outcome will be 3-year progression-free survival.

03

Conditions studied

  • Uterine Cervical Neoplasms

Keywords

  • Uterine Cervical Neoplasms
  • Nivolumab
  • Ipilimumab
  • Chemoradiation
  • Anti-PD1
  • Anti-PDL1
  • Anti-CTLA4
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants older than 18 years
  • Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO Stage IB2-IB3 node positive or Stage IIB-IVA
  • No prior chemotherapy, or radiotherapy for cervical cancer
  • performance status of 0-1
  • At least 1 lesion, not previously irradiated, that qualifies as a 1.1 Target Lesion at baseline.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of small cell (neuroendocrine) histology cervical cancer
  • Intent to administer a fertility-sparing treatment regimen
  • Undergone a previous hysterectomy
  • Evidence of disease per 1.1 including lymph nodes ≥15 mm (short axis) above the L1 cephalad body or outside the planned radiation field.
  • History of allogeneic organ transplantation
  • Active or prior documented or inflammatory disorders
  • Uncontrolled intercurrent illness
  • History of another primary and active primary immunodeficiency
  • Patients with active infection

Laboratory values that fall into:

  1. WBC count (WBC) \< 2000/μL ;
  2. \< 1500/μL;
  3. count \< 100 x 103/μL;
  4. level \< 9.0 g/dL;
  5. Serum creatinine > 1.5 x (ULN) unless is

    ≥ 40 mL/min (measured or calculated using the Cockcroft-Gault formula);

  6. (AST)/Alanine aminotransferase (ALT): > 3.0 x ULN;
  7. Total > 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of \< 3.0 x ULN);
  8. Any positive test result for virus or virus that indicates the presence of the virus, for example, positive Hepatitis B surface antigen (HBsAg, Australia antigen) or Hepatitis C antibodies (anti- HCV) positive (unless the HCV-RNA is negative).

    • Participants with a condition requiring systemic treatment or with (>10 mg daily of a prednisone equivalent) or other drugs within 14 days of initiating study treatment.
    • Pregnant or breastfeeding woman
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Active comparator
    Standard Chemoradiation

    Traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week or carboplatin AUC 2/week

    Radiation: Chemoradiation

  • Experimental
    Immunotherapy

    4 cycles of induction therapy with nivolumab 1mg/kg and ipilimumab 3mg/kg every 3 weeks followed by traditional radiation therapy with a target of 45 Gy in 25 1.8Gy fractions with concurrent weekly cisplatin 40mg/m2/week (or carboplatin AUC 2/week) with concurrent nivolumab 240mg every 2 weeks.

    Drug: Nivolumab 40 mg in 4 ml Injection · Drug: Ipilimumab 200 MG in 40 ML Injection · Radiation: Chemoradiation

Interventions

  • DrugNivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation

    Also known as: Opdivo

  • DrugIpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation

    Also known as: Yervoy

  • RadiationChemoradiation

    Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w

    Also known as: Cisplatin-based chemoradiation

06

What researchers measure

Primary outcomes

  1. 3-year progression-free survival

    No evidence of disease recurrence/regrowth after 3 years of follow-up

    Time frame: 3 years

Secondary outcomes

  1. 3-year overall survival

    Rate of survival 3 years after the end of chemoradiation

    Time frame: 3 years

  2. Objective response rate

    RECIST response

    Time frame: 90 days after the end of chemoradiation

  3. Response duration

    Time from maximum response to disease progression

    Time frame: Through study completion, an average of 3 year

  4. To evaluate health related quality of life (HRQoL): defined as the change from baseline of disease-related symptoms and quality of life of patients undergoing treatment Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

    Evaluate health related quality of life using the instrument EORTC QLQ-C30 v3 based on European Organization for Research and Treatment of Cancer (EORTC). The EORTC QLQ-C30 v3 questionnaire, consisting of 30 questions covering 15 domains, divided into three distinct scales: state scale global health and quality of life (it has only one domain, global health measure); functional scale (physical function, role performance, emotional function, cognitive function and social function domains); and symptom scale (fatigue, nausea and vomiting, pain, dyspnea, insomnia, loss of appetite, constipation, diarrhea and financial difficulties). The scores on each scale range from 0 - 100. The global and functional health scales indicate better quality of life as their score approaches 100. For the symptoms scale, the analysis is inverse, with better performance for quality of life when the scores approach the score minimum (zero).

    Time frame: Baseline (time from screening - before starting treatment) and at the end of treatment (56 days after the last dose of radiotherapy).

  5. Evaluate health related quality of life using supplemental cervical cancer module (EORTC CX24) to evaluate patients submitted to treatment with Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer.

    The EORTC - CX24 questionnaire contains 24 questions, divided into three multiple-item scales and six single-item scales, of which 11 refer to symptoms (questions 31-37, 39 and 41-43), three about body image. (questions 45-47), four questions on sexual/vaginal function (questions 50-53), one on lymphedema (question 38), one for evaluation of peripheral neuropathy (question 40), one for evaluation of menopausal symptoms (question 44) ), one on sexual concerns (question 48), one on sexual activity (question 49) and one on sexual pleasure (question 54). The answers are transformed into a score from 0 - 100 and calculated separately for each scale.

    Time frame: Baseline (time from screening - before starting treatment) and at the end of treatment (56 days after the last dose of radiotherapy).

  6. Treatment-related toxicity

    Treatment-related toxicity according to CTCAE version 4.0 (Common Toxicity Criteria for Adverse Events )

    Time frame: Through study completion, an average of 3 year

07

Study locations

6 of 14 sites recruiting
  • Clinica AMO
    Salvador, Bahia 41810-011, Brazil
    Recruiting
  • CRIO -Centro Regional Integrado de Oncologia
    Fortaleza, Ceará 60335-480, Brazil
    Recruiting
  • Hospital das Clinicas da UFMG
    Belo Horizonte, Minas Gerais 30130-100, Brazil
    Not yet recruiting
    • Angélica Nogueira · Contactangélica.onco@uol.com.br · +55(31)3307-9255
    • Angélica Nogueira, MD · Principal investigator
  • Hospital Erasto Gaertner
    Curitiba, Paraná 81520-060, Brazil
    Not yet recruiting
  • Multi Oncoclinicas Recife
    Recife, Pernambuco 50070-460, Brazil
    Recruiting
  • Hospital São Lucas - PUCRS
    Porto Alegre, Rio Grande Do Sul 90610-001, Brazil
    Not yet recruiting
  • Universidade Federal de Roraima
    Boa Vista, Roraima 69310-000, Brazil
    Recruiting
  • CEPON - Florianópolis
    Florianópolis, Santa Catarina 88034-000, Brazil
    Not yet recruiting
    • Anne Schmitz · Contactanneschmitz@uol.com.br · +55(48)3331-1553
    • Anne Schmitz, MD · Principal investigator
  • Hospital de Amor
    Barretos, São Paulo 14784-400, Brazil
    Not yet recruiting
    • Maria Fernanda Biazzotto · Contactnandabiazotto@hotmail.com · +55(17)3321-6638
    • Maria Fernanca Biazzotto, MD · Principal investigator
  • Hospital De Base de São José do Rio Preto - CIP São José
    São José Do Rio Preto, São Paulo 15090-000, Brazil
    Not yet recruiting
    • João Daniel · Contactjoaodcguedes@gmail.com · +55(17)3201-5054
    • João Daniel, MD · Principal investigator
  • INCA - Instituto Nacional do Cancer
    Rio De Janeiro, 20230-130, Brazil
    Not yet recruiting
  • AC Camargo Cancer Center
    São Paulo, 01509-001, Brazil
    Not yet recruiting
  • Hospital Municipal Vila Santa Catarina
    São Paulo, 04378-500, Brazil
    Recruiting
    • Ana Lucia Neves · Contactana.neves@einstein.br · 2151-1223
    • Henrique A Helber, MD · Principal investigator
  • Hospital Israelita Albert Einstein
    São Paulo, 05652-900, Brazil
    Recruiting
    • Fernando Maluf · Contact
    • Diogo Bugano · Contactdiogo.gomes@einstein.br
    • Fernando Maluf · Principal investigator
08

References and documents

Publications

  • Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008 Dec 10;26(35):5802-12. doi: 10.1200/JCO.2008.16.4368. Epub 2008 Nov 10. PubMed 19001332 ↗
  • Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, Lopez-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. PubMed 31487218 ↗
  • Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 Apr;157(1):161-166. doi: 10.1016/j.ygyno.2019.12.034. Epub 2020 Jan 7. PubMed 31924334 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

Of 155 non-industry phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 52 months is above that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2022
First posted
Aug 8, 2022
StartActual
Aug 30, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2028
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05492123
Collaborators
Bristol-Myers Squibb, Brava
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Aug 30, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jan 5, 2024

Study contacts

Diogo Bugano, MD
Contact
diogo.gomes@einstein.br
+55-11-2151-0240
Fernando Maluf, MD
principal investigator · Hospital Israelita Albert Einstein

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion